[go: up one dir, main page]

PL3999069T3 - Synergistyczne działanie eyp001 i pegylowanego ifn-alfa w leczeniu zakażenia hbv - Google Patents

Synergistyczne działanie eyp001 i pegylowanego ifn-alfa w leczeniu zakażenia hbv

Info

Publication number
PL3999069T3
PL3999069T3 PL20740022.7T PL20740022T PL3999069T3 PL 3999069 T3 PL3999069 T3 PL 3999069T3 PL 20740022 T PL20740022 T PL 20740022T PL 3999069 T3 PL3999069 T3 PL 3999069T3
Authority
PL
Poland
Prior art keywords
eyp001
alfa
treatment
synergistic effect
hbv infection
Prior art date
Application number
PL20740022.7T
Other languages
English (en)
Inventor
Jacky Vonderscher
Elise ROY
Raphaël Darteil
Pietro Scalfaro
Original Assignee
Enyo Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enyo Pharma filed Critical Enyo Pharma
Publication of PL3999069T3 publication Critical patent/PL3999069T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL20740022.7T 2019-07-18 2020-07-17 Synergistyczne działanie eyp001 i pegylowanego ifn-alfa w leczeniu zakażenia hbv PL3999069T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19186941 2019-07-18
PCT/EP2020/070241 WO2021009333A1 (en) 2019-07-18 2020-07-17 Synergistic effect of eyp001 and ifn for the treatment of hbv infection

Publications (1)

Publication Number Publication Date
PL3999069T3 true PL3999069T3 (pl) 2024-03-25

Family

ID=67437952

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20740022.7T PL3999069T3 (pl) 2019-07-18 2020-07-17 Synergistyczne działanie eyp001 i pegylowanego ifn-alfa w leczeniu zakażenia hbv

Country Status (12)

Country Link
US (1) US20220313690A1 (pl)
EP (1) EP3999069B1 (pl)
JP (1) JP7376679B2 (pl)
KR (1) KR102662826B1 (pl)
CN (1) CN114051411B (pl)
AU (1) AU2020314081B2 (pl)
CA (1) CA3140325C (pl)
ES (1) ES2968931T3 (pl)
IL (1) IL289069B2 (pl)
MX (1) MX2021016022A (pl)
PL (1) PL3999069T3 (pl)
WO (1) WO2021009333A1 (pl)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1238053C (zh) * 2002-12-02 2006-01-25 美德(江西)生物科技有限公司 含alfa-干扰素,拉米夫定和阿地福韦酯的药包
EP1886685A1 (en) * 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
CZ2007494A3 (cs) * 2007-07-20 2008-11-12 Ceské vysoké ucení technické v Praze Optický clen pro rentgenovou mikroskopii
RU2013148779A (ru) * 2011-04-01 2015-05-10 Новартис Аг Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени
MX377523B (es) 2013-09-11 2025-03-10 Inst Nat Sante Rech Med Metodos y composiciones farmaceuticas para el tratamiento de la infeccion por el virus de la hepatitis b.
WO2018222910A1 (en) * 2017-05-31 2018-12-06 Arbutus Biopharma Corporation Therapeutic compositions and methods for treating hepatitis b
CN107441098A (zh) * 2017-06-28 2017-12-08 河南大学 Fxr拮抗剂在在制备抗hbv药物中的应用

Also Published As

Publication number Publication date
EP3999069C0 (en) 2023-10-11
IL289069A (en) 2022-02-01
EP3999069A1 (en) 2022-05-25
AU2020314081B2 (en) 2025-09-11
CN114051411B (zh) 2022-10-28
JP7376679B2 (ja) 2023-11-08
IL289069B (en) 2022-11-01
WO2021009333A1 (en) 2021-01-21
CA3140325C (en) 2022-07-19
CN114051411A (zh) 2022-02-15
MX2021016022A (es) 2022-02-03
IL289069B2 (en) 2023-03-01
KR20220035437A (ko) 2022-03-22
ES2968931T3 (es) 2024-05-14
KR102662826B1 (ko) 2024-05-03
JP2022540697A (ja) 2022-09-16
US20220313690A1 (en) 2022-10-06
EP3999069B1 (en) 2023-10-11
CA3140325A1 (en) 2021-01-21
AU2020314081A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
PL3661954T3 (pl) Muteiny interleukiny 21 i sposoby leczenia
IL281277A (en) Preparations and methods for treating viral infections
HUE058931T2 (hu) Pilokarpin hidroklorid alkalmazása presbyopia kezelésére
IL290792A (en) Preparations and methods for treating viral infections
EP3288957A4 (en) NUCLEOSIDE ANALOGUE FOR THE TREATMENT OF VIRUSES OF THE FLAVIVIIDAE FAMILY AND CANCER
PL3556377T3 (pl) Dalargin do stosowania w leczeniu ostrych infekcji wirusowych dróg oddechowych
EP4017924A4 (en) SURFACE TREATMENT COMPOSITIONS AND METHODS
SI3947375T1 (sl) Imidazolonilkinolinske spojine in terapevtske uporabe le-teh
EP3830196A4 (en) SURFACE TREATMENT COMPOSITIONS AND METHODS
PL3972643T3 (pl) Antagoniści układu dopełniacza do stosowania w sposobach leczenia neuropatii paraproteinemicznych
LT3586837T (lt) Kompozicijos, apimančios aminorūgštis, skirtos panaudoti kepenų ligų prevencijai ir gydymui
MX393900B (es) Uso de gaboxadol en el tratamiento de tinnitus.
PL3759083T3 (pl) Pochodne 2,4-diaminochinazoliny i ich zastosowanie w leczeniu zakażeń wirusowych, nowotworu lub alergii
EP3541401A4 (en) TREATMENT OF RESPIRATORY TRACT INFECTIONS AND DISEASES WITH GLUTATHION COMPOSITIONS
IL263988A (en) Compositions useful in the prevention and/or treatment of osteoarticular inflammation and pain and cartilage damage
EP4003355A4 (en) DIHYDROPYRIMIDE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASE
IL264407A (en) Novel application of gzd824 and pharmaceutically acceptable salts thereof in treating diseases
EP3814326A4 (en) DIHYDROPYRIMIDINE DERIVATIVES AND THEIR USES IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR HEPATITIS B VIRUS INDUCED DISEASES
PL3463469T3 (pl) Kombinacja ledipaswiru i sofosbuwiru do zastosowania w leczeniu zakażeń wirusem zapalenia wątroby typu b u ludzi
EP3790866A4 (en) DIHYDROPYRIMIDINE DERIVATIVES AND THEIR USES IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR HEPATITIS B VIRUS INDUCED DISEASES
PL3823623T3 (pl) Podstawiony związek aminopirymidynowy do zastosowania w metodzie leczenia i zapobiegania stwardnieniu rozsianemu
IL290192A (en) Nitanin analogs and their use in the treatment of chronic and acute pain
PL3630112T3 (pl) Kombinacja regorafenibu i niwolumabu w leczeniu nowotworu
PL3999069T3 (pl) Synergistyczne działanie eyp001 i pegylowanego ifn-alfa w leczeniu zakażenia hbv
EP4003987A4 (en) DIHYDROPYRIMIDINE DERIVATIVES AND THEIR USES IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR HEPATITIS B VIRUS INDUCED DISEASES